CombiGene conducts Extraordinary General Meeting
December 2, 2024
CombiGene AB (publ) (“CombiGene”, the “Company”) hereby reminds its shareholders to attend the Extraordinary General Meeting
CombiGene AB (publ) (“CombiGene”, the “Company”) hereby reminds its shareholders to attend the Extraordinary General Meeting
The shareholders of CombiGene AB (publ) (“CombiGene” or the “Company”) have previously been given notice to
The shareholders of CombiGene AB (publ) reg. no. 556403-3818, (the “Company”) are hereby given notice to
The Board of Directors of CombiGene AB (publ) (“CombiGene” or the “Company”) has received proposals for
CombiGene AB (publ) (“CombiGene”, “the Company”) announces today that it intends to sharpen its strategic focus
CombiGene AB (publ) (“CombiGene”, the “Company”) today announces preliminary results from completed analyzes of the latest
CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Västra Hamnen Corporate Finance, in its initial
CombiGene AB (publ) (“CombiGene”, “the Company”) today announces that the Company has entered into a license
CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that the company intends to change Certified Adviser
CombiGene AB (publ) (“CombiGene”, the “Company”) announces today that Annika Ericsson, current Director Preclinical Development, will